Aduro Biotech (ADRO) Says Milestone Achieved under Merck Pact for Initiation of Anti-CD27 Phase I Trial in Advanced Solid Tumors
Tweet Send to a Friend
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that the company earned a $3.0 million development milestone payment under its worldwide ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
